News for Cardiff Oncology, Inc. (CRDF)

Cardiff Oncology, a clinical-stage biotechnology firm, develops novel therapies for the treatment of various cancers. Read why I reaffirm my buy rating on CRDF.

Massachusetts-based Replimune Group, Inc. (REPL) is over 68 percent in Wednesday's pre-market trading. The following are some of the other stocks making big moves in Wednesday's pre-market trading.

U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Wednesday. Shares of Avis Budget Group, Inc. CAR fell sharply in pre-ma...

Shares of LendingClub Corporation LC rose sharply in pre-market trading after the company reported better-than-expected second-quarter sales results. LendingCl...

- Appointed Dr. Roger Sidhu as Chief Medical Officer -

- Trial demonstrates 49% confirmed ORR in the 30mg onvansertib dose arm versus 30% confirmed ORR in the control arm in intent-to-treat population (N=110) -

Cardiff Oncology Inc. (CRDF), a clinical-stage biotechnology company, is expected to share additional clinical data from its ongoing CRDF-004 trial on July 29, 2025.

Cardiff Oncology’s trial delay and leadership change stir volatility, but strong data potential and a solid cash runway offer upside. Read why CRDF is a buy.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Cardiff Oncology (CRDF) has announced a transition in its medical leadership alongside plans to reveal new clinical data from its ongoing CRDF-004 trial. This u

”“ Veteran executive with over 20 years of oncology leadership and clinical experience with proven track record of success in bringing development candidates t

Cardiff Oncology, under the ticker CRDF, has announced the appointment of Roger Sidhu as its new chief medical officer. Sidhu brings over two decades of experie

Cardiff Oncology, Inc.

Cardiff Oncology (CRDF) has revealed encouraging outcomes from a Phase 1b clinical study focusing on onvansertib, used in conjunction with paclitaxel, as a trea

Cardiff Oncology is entering a pivotal stage with a strong cash runway and compelling early data in first-line RAS-mutant mCRC. Click to read why CRDF is a Buy.

Cardiff Oncology (CRDF), a prominent player in the biopharmaceutical sector, received a significant endorsement from HC Wainwright & Co., a reputable financial

Cardiff Oncology (CRDF) reported its first-quarter revenue of $109,000, surpassing expectations of $89,290. The company's lead initiative, focusing on onvansert

We recently published a list of 10 Hot Biotech Stocks Under $5. In this article, we are going to take a look at where Cardiff Oncology, Inc.